国际医学影像信息技术与网络安全公司Sectra完成对Oxipit的收购，加速放射学中的自主人工智能发展-动脉网

Sectra completes Oxipit acquisition, accelerating autonomous AI in radiology

PR Newswire 等信源发布 2026-04-15 14:58



可切换为仅中文







LINKÖPING, Sweden

林雪平，瑞典

，

April 15, 2026

2026年4月15日

/PRNewswire/ --

International medical imaging IT and cybersecurity company

国际医疗影像IT与网络安全公司

Sectra

赛克特拉

(STO: SECT B)

（斯托：B部分）

has completed the acquisition of Oxipit, a pioneer in autonomous AI for radiology and the developer of the first solution with CE Class IIB certification for autonomous chest X-ray analysis. This milestone strengthens Sectra's position as a provider of advanced, regulatory-approved AI solutions for diagnostic imaging..

已完成对Oxipit的收购，该公司是放射学领域自主人工智能的先驱，并开发了首个获得CE Class IIB认证的自主胸部X光分析解决方案。这一里程碑进一步巩固了Sectra作为先进、监管批准的诊断影像AI解决方案提供商的地位。

'With the acquisition of Oxipit, we're adding a new dimension to our AI offering: autonomous AI that can genuinely reduce radiologists' workload in daily clinical practice. Equally important, we're acquiring the clinical validation and regulatory expertise required to deploy this category of AI responsibly at scale.

“通过收购Oxipit，我们为自己的人工智能产品增添了新的维度：能够真正减轻放射科医生日常工作负担的自主人工智能。同样重要的是，我们正在获取临床验证和监管方面的专业知识，以负责任地大规模部署这类人工智能。”

The acquisition complements our vendor-neutral AI marketplace, which remains a cornerstone of our strategy, and our own rapid innovation such as MCP-powered system administration. Together, these moves demonstrate clear leadership in AI for diagnostic imaging and position us to help healthcare providers manage rising imaging volumes and address staff burnout,' says Torbjörn Kronander, President and CEO of Sectra..

“此次收购完善了我们与供应商无关的人工智能市场，该市场仍然是我们战略的基石，也推动了我们自身的快速创新，例如基于MCP的系统管理。这些举措共同展示了我们在诊断影像人工智能领域的明确领导地位，并使我们能够帮助医疗服务提供者管理不断增长的影像数量并解决员工倦怠问题。” Sectra总裁兼首席执行官托比约恩·克罗纳德表示。

With the acquisition complete, Sectra now owns and will further develop ChestLink, Oxipit's flagship product and one of the most clinically validated examples of autonomous AI in radiology. Unlike conventional AI decision-support tools, which flag findings or assist prioritization but leave reporting to the radiologist, autonomous AI is developed and validated to independently complete a defined diagnostic task.

随着收购的完成，Sectra现在拥有并将进一步开发Oxipit的旗舰产品ChestLink，这是放射学领域中临床验证最充分的自主人工智能实例之一。与传统的AI决策支持工具不同——这些工具标记检查结果或协助优先级排序，但将报告工作留给放射科医生——自主AI被开发和验证为能够独立完成特定的诊断任务。

ChestLink automatically identifies and clears high-confidence normal chest X-rays from the worklist, freeing radiologists to focus on cases with a higher probability of disease. The product holds CE Class IIb certification*, reflecting the rigorous safety and regulatory standards required for this category of AI..

ChestLink 会自动识别并清除工作列表中高可信度的正常胸部 X 光片，使放射科医生能够专注于有更高患病概率的病例。该产品拥有 CE IIb 类认证*，反映了此类 AI 所需的严格安全和监管标准。

Answers to frequently asked questions about the acquisition are available on our website>>.

有关收购的常见问题解答，请访问我们的网站>>。

* CE class IIb certification confirms compliance with EU medical device regulations and permits commercialization within the EEA.

* CE IIb类认证确认符合欧盟医疗器械法规，并允许在欧洲经济区内商业化。

For further information, please contact:

如需更多信息，请联系：

Dr. Torbjörn Kronander, CEO and President Sectra AB, +46 (0)705 23 52 27

托比约恩·克罗纳德博士， Sectra AB公司首席执行官兼总裁，+46 (0)705 23 52 27

Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, +46 (0)708 23 56 10

玛丽·埃克斯特罗姆·特拉加德，Sectra AB执行副总裁兼Sectra影像IT解决方案总裁，+46 (0)708 23 56 10

This information was brought to you by Cision